摘要
目的探讨利伐沙班治疗急性中危肺血栓栓塞合并下肢深静脉血栓临床研究。方法选择2017年1月至2018年9月期间我院接受诊治的急性中危肺血栓栓塞合并下肢深静脉血栓患者85例。根据随机数字表法将85例患者随机分为对照组(n=42)与治疗组(n=43)。对照组皮下注射低分子肝素钠,口服华法林;治疗组在对照组基础上结合利伐沙班。两组疗程均为14d。比较两组治疗前与治疗后肢体周径差、Miller指数评分和VAS评分变化,及治疗总有效率。结果两组治疗后肢体周径差较治疗前降低(治疗组:t=11.707,对照组:t=6.930,P<0.05);治疗组治疗后肢体周径差低于对照组(t=8.239,P<0.05)。两组治疗后Miller指数评分较治疗前降低(治疗组:t=25.524,对照组:t=17.964,P<0.05);治疗组治疗后Miller指数评分低于对照组(t=19.362,P<0.05)。两组治疗后VAS评分较治疗前降低(治疗组:t=31.596,对照组:t=21.864,P<0.05);治疗组治疗后VAS评分低于对照组(t=14.123,P<0.05)。治疗组总有效率(90.70%)高于对照组(66.67%)(P<0.05)。结论利伐沙班治疗急性中危肺血栓栓塞合并下肢深静脉血栓临床疗效显著,具有重要临床研究价值。
Objective To investigate the clinical study of rivaroxaban in treatment of acute and moderate-risk pulmonary thromboembolism with deep venous thrombosis of lower extremities.Methods From January 2017 to September 2018,85 patients with acute moderate-risk pulmonary thromboembolism and deep venous thrombosis of lower extremities were selected,and they were randomly divided into the control group ( n =42) and the treatment group ( n =43).The control group was subcutaneously injected with low molecular weight heparin sodium and orally administered warfarin,while the treatment group was combined with rivaroxaban on the basis of the control group.The two groups were treated for 14 days.The changes of limb circumference difference,Miller index score and VAS score before and after treatment were compared between the two groups,and the total effective rate of treatment was also compared.Results After treatment,the difference of limb circumference between the two groups was lower than before treatment (the treatment group:t =11.707;the control group:t =6.930,P< 0.05).The difference of limb circumference in the treatment group was lower than that in the control group ( t=8.239,P< 0.05).After treatment,the Miller index score of the two groups was lower than before treatment (the treatment group:t =25.524;the control group:t =17.964,P< 0.05).After treatment,the Miller index score of the treatment group was lower than that of the control group ( t =19.362,P< 0.05).After treatment,the VAS score of the two groups was lower than before treatment (the treatment group:t =31.596;the control group:t =21.864,P< 0.05).The VAS score of the treatment group was lower than that of the control group ( t =14.123,P< 0.05).The total effective rate of the treatment group (90.70%) was higher than that of the control group (66.67%)( P< 0.05).Conclusion Rivaroxaban is effective in treatment of acute and moderate-risk pulmonary thromboembolism with deep venous thrombosis of lower extremities,and has important clinical research value.
作者
张乐
童翩
谷春玲
胡广成
柴沛
杨冬玉
ZHANG Le;TONG Pian;GU Chun-ling;HU Guang-cheng;CHAI Pei;YANG Dong-yu(Department of Respiratory Medicine,Sanmenxia Hospital of Yellow River,Sanmenxia,Henan 472000,China)
出处
《临床肺科杂志》
2019年第8期1406-1409,共4页
Journal of Clinical Pulmonary Medicine
关键词
利伐沙班
急性中危肺血栓栓塞
下肢深静脉血栓
rivaroxaban
acute middle risk pulmonary thromboembolism
deep vein thrombosis of lower extremity
